Robert Hauver publishes The Double Dividend Stock Alert, a monthly investment newsletter that features the best dividend stocks and option selling strategies for income investors.
TipRanks rates DoubleDividendStocks in the Top 25 of all financial bloggers.
The https://www.DoubleDividendStocks.com website also features High Dividend Stocks By Sector Tables, and Covered Calls & Cash Secured Puts Tables, a Dividend Stocks blog, and a a Stock Market News & Data page. 845-225-4094
I am a former engineer in topography (ESGT Paris 80) and specialized later in metrology or very precise measurement (CERN). I was interested in quantum metrology for a while...
I live mostly between California (Santa Monica), Provence-Cote d'azur (Where my children and grand children live mostly) and Sweden (South West Skåne) with my loving wife.
I am taking care of a large family fund and also, trade personally a medium-size portfolio for over 25 years. “Logic will get you from A to B. Imagination will take you everywhere.” Einstein.
I am a dividend investor and look for undervalued investments in the stock market. I identify misunderstood and undervalued equity investments and hold those securities until their price approximates my estimate of intrinsic value. I am a long-term investor only.
I am building a $100,000 high-yield income portfolio. I am running this portfolio as an experiment to see if long-term sustainable income can be generated from a diversified pool of high-risk, high-yield securities. I am willing to accept high risk in order to meet my performance goals.
Brad Thomas is a research analyst and he currently writes weekly for Forbes and Seeking Alpha where he maintains research on many publicly-listed REITs. In addition, Thomas is the Senior Analyst at iREIT Forbes and Editor of the Forbes Real Estate Investor, a monthly subscription-based newsletter.
Thomas has also been featured in Forbes Magazine, Kiplinger’s, US News & World Report, Money, NPR, Institutional Investor, GlobeStreet, and Fox Business. He was the #1 contributing analyst on Seeking Alpha in 2014 (as ranked by TipRanks) and he is currently writing a book on the legendary investor Donald Trump. In addition, Thomas is co-authoring a book (The Intelligent REIT Investor) that will e published in August 2016.
Thomas received a Bachelor of Science degree in Business/Economics from Presbyterian College where he played basketball. He resides in South Carolina with his wife and kids.
A former stockbroker who became licensed in 1986. Later opened a small hedge fund and managed a modest amount of assets. Then retired to my current status of individual investor where I simply manage my own money and enjoy sharing ideas that I hope will bring some value.
We are now building a resource for those interested in the wearables industry, including mHealth, virtual reality, augmented reality, and wrist wearables, etc. Our focus includes companies, technology, and trends that are innovating and disrupting healthcare, communications, computing, and other industries. This resource is known as Wearables Go! We hope that investors and industry professionals will find this resource useful. It will be coming soon to the SA Marketplace. Please be sure to follow Bull & Bear Trading for updates and future articles.
I am a former Investment and Commercial Banker with over 30 years experience in the field. I have been advising both individuals and institutional clients on high-yield investment strategies since 1991. As author of “High Dividend Opportunities”, a premium subscription service at Seeking Alpha, my objective is to bring investors the most profitable and newest high dividend ideas, with special focus on the Energy sector. The service includes an actively managed model Portfolio targeting an overall dividend yield of 6-9% in addition to long-term capital gains. My research aims to maximize returns by identifying undervalued securities in the High Yield space.
In addition to being a Certified Public Accountant CPA from the State of Arizona, I hold a BS Degree from Indiana University, Bloomington, and a Masters degree from Thunderbird School of Global Management (Arizona). I am also a Certified Mortgage Advisor CEMAP, a UK certification. My Research and Articles have been featured on Seeking Alpha, Investing.com, ETFdailynews, and on FXEmpire.
For more information on how to subscribe to “High Dividend Opportunities” and gain exclusive access to the portfolio, live alerts and market commentaries, check the post: Introduction to “High Dividend Opportunities” on my Instablog or just email me at firstname.lastname@example.org .
Chris DeMuth Jr. is the founder of Rangeley Capital LLC. Rangeley is an investment firm that focuses on event driven, value-oriented investment opportunities. Rangeley Capital and his value investing forum, Sifting the World (StW), search the world for misplaced bets. Rangeley exploits them for its investors and then Mr. DeMuth writes about them on StW.
Formerly Chief Market Strategist at Capital Ladders Advisory Group LLC. After the sale of certain of CLAG's retail and institutional assets in October 2015, I have commenced my latest venture in the CPG industry which is centered on the development and licensing of consumer and commercial technology. https://www.linkedin.com/profile/view?id=AAIAAA3lJ9IBNi1rhhFzRWElkJl4MpyNuIiHglQ&trk=nav_responsive_tab_profile
CooLinX Integrated Technologies develops technologies for the beverage and CPG industry. We are presently effecting licensing agreements with multi-national brands and co-developing products aimed for mass market consumption.
If you are interested in any of my digital utility solutions to add to your investing tool box to improve your investment outcomes, please visit my site
You'll find elegant applications that make it simple for you to track your portfolio in real time, make a watch list to follow in real time, track your dividend income and growth, and other applications. These applications will allow you to set alerts at prices you choose in order to obtain the yield and income that you want. They function as real time trade assistants and will improve your investment performance. You can even mirror the successful FTG Portfolio with "My FTG Mirror Calculator", and subscribers can mirror the premium subscriber portfolio with "MY RODAT Mirror Calculator" if they wish to emulate the out performance we've achieved in capital and income growth.
I am a retired clinical psychologist, and administrator and owner of a rehabilitation clinic we founded 40 years ago. For over 55 years I have managed several portfolios composed of investments accumulated over our professional careers. Since the financial crisis of 2008, I have employed specialized, customized dividend growth strategies aimed at enhancing and growing a dividend income stream.
Since December 24, 2014, I have demonstrated on Seeking Alpha the ongoing construction and portfolio management of the Fill-The-Gap Portfolio aimed at highlighting strategies investors may utilize to close the gap between an average Social Security benefit and the much greater costs faced in retirement.
This portfolio has outperformed all of the broad market indexes by a very wide margin, growing dividend income and total portfolio value consistently while the broader indexes struggle in negative territory all year.
Aside from free articles available to the general public, additional early-access, value-added ideas and deep-dive articles are offered to paid subscribers on my premium SA platform, "Retirement: One Dividend At A Time"
Let me show you how to build and grow your portfolio and dividend income, step by step, towards a comfortable and secure retirement.
I've been an investment analyst and financial writer since 2012. I hold a Bachelor's degree in Finance from DePaul University, and an MBA in Finance from the University of Notre Dame. I also have experience working as a research analyst for a mutual fund.
I like exposing Penny Stock Pump and Dumps. Most of my research is done to help good hard working people avoid being scammed into investing in a pump and dump. Share the reports to show Seeking Alpha they are worth publishing this kind of information to help people avoid losing money in pump and dumps.
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases.
To contact Derek, email him directly: email@example.com (mailto:firstname.lastname@example.org)
We are Lowenthal Capital Partners, an investment group managed by Trevor Lowenthal located in Davis, California. Trevor graduated with a BA in Political Science from University of California, Davis with Summa Cum Laude distinction. He is currently a Juris Doctor candidate at University of Colorado Boulder, specializing in Health Law.
My trading experience includes over twenty five years of intense investment analysis, trend analysis and deep level due diligence studies. My interest is to find small company opportunities that have established funding sources, have a plan of action and are in the preliminary to first stages of pipeline development and execution.
My coverage and investment interest includes biotech, small cap and emerging growth companies, regardless of sector.
Arthur Porcari is a retired former regional stock brokerage firm President with 40 years stock market experience. His finance background includes, three years a stockbroker and two an investment banker with Merrill Lynch, ten years a Regional brokerage firm President, and OTC Market Maker and Analyst, twenty three years an Investment Banker to include 15 years as Managing Consultant to Corporate Strategies, Inc. a firm specializing in advising young public companies and companies about to go public on the “Ways of Wall Street”. He currently is a Contributing Author and blogger on Seeking Alpha under his own name and has in the past been an on-air guest as well has a guest host on the old Financial News News Network TV channel and more recently on Business Talk Radio Network His passion and particular expertise is for small cap emerging growth companies.
“Full Disclosure under Seeking Alpha author rules: 25 years ago in 1988, after I sold my brokerage firm and left the Industry, my FINRA license was revoked for non-payment of a fine assessed a year later in 1989. The fine was the result of a minor record keeping violation that was levied on my brokerage firm and as President, I was held responsible but was only required to pay it if I elected to go back in the brokerage business.“
I have been investing in the stock market as a personal investor for approximately ten years now. I began my training in an accelerated pre-med program, and have continued both my interest and research in related topics. I only invest in companies after very lengthy deliberation, although am apt to leave the market entirely for periods of time. I have almost exclusively traded in the biotech sector.
I am interested in finding deep value ideas and sharing the findings of my due diligence with readers to encourage a healthy level of discussion. All material in my articles or posts represent my own personal views only. None of my content constitutes any recommendation, financial/investment advice, offer or solicitation to buy or sell any securities. No warranty of accuracy, timeliness, or completeness is given. Reliance upon my content is at the sole discretion of the reader.
I've made the decision to no longer contribute content on this platform. I've done so due to irreconcilable differences of opinion with the editors of Seeking Alpha regarding what I believe to be inconsistent, absent and deeply biased editorial oversight. Favoritism is the motive that moves these decisions and is granted not on the basis of merit, but on thematic considerations (short-position articles are given massive leeway) and on pragmatic considerations (who can make Seeking Alpha the most money). For readers, this creates a problematic environment where a marketplace of competing ideas is crushed in favor of compliance to preconceived and sterile thinking. Participation in "The Marketplace" is coerced in order for one's contributions to be labelled "premium" even if that content is far from the meaning that the word "premium" implies. Additionally, certain contributors are allowed to play by their own rules and in so doing the well being of all investors is compromised. While I applaud the idea of moving the markets through well researched and articulated ideation, I deplore manipulation of the market through false pretense and deliberate, unethical and morally repugnant activities. When I have brought my concerns to the editors, I've been told unequivocally that these matters don't concern them or, alternatively, that they do not wish to play the role of regulators. In both instances, I find these responses unacceptable if only because the core idea of Seeking Alpha as the democratization of the stock market through the publication of buy-side analysis is so worth protecting. I leave you, my readers, with a deep sense of gratitude for all the encouragement you've given me. In my absence, I ask only that you do your own due diligence and recognize that the opinions of bloggers, such as myself, are not to be acted upon. No opinion expressed by any contributor, most especially myself, constitutes an offer or suggestion to buy, sell, or hold any security. Always consult an investment professional before making any investment decision. In the absence of professional guidance, learn all that you can about one particular sector of investment. Follow the development of not only the companies involved, but the science, technology and persons associated with the business sector you've chosen. Remember your successes and learn from your mistakes.
Always be well...
P.S. Scrying Biotech is not, and has never been a pseudonym. It's just the coolest logo in biotech blogging. My name is, Michael Webb. And I live in the greatest city on earth - Seattle, Washington.
I am an independent equity research analyst and consultant. I focus on finding small-cap biotech stocks where I believe there is favorable risk / reward because of misinformation, lack of information, or a potential fundamental turnaround. I provide detail analysis for investors and investor relations companies. I also provide due diligence and advisory services to companies. Some names I write on I invest in personally and will disclose my position. Names that have hired me to provide due diligence or advisory services I will disclose a business relationship.
I previously worked for Zacks Investment Research from 2003 to 2015 as a Senior Biotechnology Analyst. Prior to Zacks, I spent 1999 to 2002 managing money with Eastover Capital in Charlotte, NC where I focused on large-cap equities, specializing in healthcare, energy, and technology. Prior to joining Eastover, I worked as a research scientist for TechLab, Inc., a biotechnology company focused on developing diagnostic kits and vaccines for infectious diseases, between 1995 and 1998. I also spent a year working at the Fralin Biotechnology Center, and a year working for a cancer researcher while at Virginia Tech.
I have a B.S. in Biochemistry from Virginia Tech, with a B.A in Chemistry and a minor in Math. I have a M.B.A. in Finance, with a concentration in Securities Analysis, from Wake Forest University. I hold the Chartered Financial Analyst (CFA) designation.
I retired as CEO of an Automotive Parts supplier, and manage an investment portfolio for myself and family. I have a BA in History from Royal Military College of Canada and an MBA from the University of Western Ontario. My first career was as a fighter pilot in the RCAF, and, following my MBA I joined McKinsey & Company, Inc. leaving them for Canadian GE. I left CGE as a Vice President in 1984 and founded The Enfield Corporation Limited ("Enfield") which grew from 243 employees in 1984 to over 10,000 in 1989 when Enfield was taken over and I was replaced as CEO. In 1989, I acquired control of Algonquin Mercantile Corporation, renamed Automodular Corporation in the late 1990's when I turned it to focus exclusively on automotive parts sub-assembly. Along the way, Algonquin turned a few ageing drug stores into Pharmx Rexall Drug Stores Ltd., sold to Katz group in 1997 and today a major Canadian drug store chain.
I have been a private investor since 1971 both directly and through a private company controlled by myself and members of my family.
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
Investor focused primarily on the Biotech Industry. I look for undervalued companies with strong management, unmet disease state and quality pipeline. I have worked in the biotech industry for many years and have a strong background in science and statistics.
Stock investment appears to me more like art than science simply because what we are dealing with are nothing else but other human minds. It is this very fact that adds the majority of complexity to stock investment. Develop a thorough understanding of psychology and human nature is the first step towards success in one's investment.
Healthcare (developmental micro-cap biotech in particular) is what attracts me most. This is the sector that produces the most number of 100% gainers in any given year, and thus gives value investors the best opportunity to buy undervalued stocks that have yet to appreciate. In this particular sector, I believe 100% or more annualized return can be achieved if invest wisely (plus some luck of course). Personally, I only look at those stocks that have the potential to at least double over a twelve-month period while taking the least amount of risk.
Part of my investment philosophy is reflected in the following remarks,
re. general market
a) Mr. Market would not correct itself JUST for the purpose of correction.
b) "It truly is a market of stocks and not a stock market; therefore, the broad stock market has little to do with the performance of individuals stocks."
c) "Fear is the foe of the faddist but the friend of the fundamentalist."
d) "The stock market is filled with individuals who know the price of everything, but the value of nothing."
e) "Doing nothing is one of the most under-appreciated skills in investing."
f) "The desire for constant action irrespective of underlying conditions is responsible for many losses in Wall Street even among the professionals, who feel that they must take home some money everyday, as though they were working for regular wages."
g) "Risk is when you don't know what you are doing."
h) "It's not what you buy. It's how much you pay for it."
i) "A pessimist sees the difficulty in every opportunity; an optimist sees the opportunity in every difficulty."
j) For true value investors, high return doesn't always come with high risk.
a) "Companies with management that engage in stock promotion mainly focused on its price per share often tend to fail in executing its core business initiatives."
re. healthcare in general
a) The beauty of stock market is in biotech; and the beauty of biotech is in nano cap.
b) "Surety in biotech, after all, is an illusion few of us can afford."
"Success in life comes when you simply refuse to give up, with goals so strong that obstacles, failure, and loss only act as motivation."
I research early (micro cap) and mid phase publicly traded companies in the Biotechnology and Medical Device sectors that are harder to at times find information on for investors. I believe that these companies, although potentially more volatile than their larger cap retail counterparts, hold great value. With a clear understanding of where their product is positioned in the market, the capitalization and the team, these smaller companies can hold incredible value over the long term.
I have a varied background in both business and in the technical sector. Currently, I also am a co founder of BCN Biosciences in Pasadena CA, a privately held biotechnology company in addition to holding a research faculty position at the University of California Los Angeles Department of Radiation Oncology.
Stephen Simpson, CFA, is a freelance financial writer and investor.
I have worked for both sell-side and buy-side firms (equities and fixed income), with the largest percentage of my working time spent in med-tech. At this point I am now effectively in a "working retirement".
As I am helping my partner of 20+ years in her battle against stage IV cancer, I don't really have the time to be very involved with comments. Likewise, I may not be able to update a particular story/situation/investment idea in an especially timely fashion.
I write because I find that the process helps me take better notes, be more disciplined about modeling, and come up with a more coherent investment view for my portfolio management needs. If I'm writing about a stock, it's generally because I'm interested in it as an investment prospect or I think there's an interesting story to tell.
I don't share my models, so please don't ask.
More of my writings can be found at my blog Kratisto Investing (kratistoinvesting.blogspot.com), or Twitter (@Kratisto_Invest).
Charles Lewis Sizemore, CFA is the Chief Investment Officer of Sizemore Capital Management LLC, a registered investment advisor. He has been a frequent guest on Bloomberg TV and Fox Business News, has been quoted in Barron’s Magazine, The Wall Street Journal, and The Washington Post and is a frequent contributor to Forbes Moneybuilder, GuruFocus, MarketWatch and InvestorPlace.com.
Charles holds a master’s degree in Finance and Accounting from the London School of Economics in the United Kingdom and a Bachelor of Business Administration in Finance with an International Emphasis from Texas Christian University in Fort Worth, Texas, where he graduated Magna Cum Laude and as a Phi Beta Kappa scholar.
Founder of insidewallstreet.org uncovering select special situation stocks.
California Real Estate Broker
Author of the erotic novel based on a true story " In Search of a Soul Mate"
CEO and President of Gibralter Financial and Real Estate Services from 2001 to 2008.
CEO of All Valley Mortgage 1993-1995
Private investor, Author and trader from 1999 to present.
Currently working as an Equity Analyst, where I focus on investment idea generation through detailed financial analysis and company contact.
Prior to this, I was working as an investment analyst responsible for idea generation at a boutique small cap equities manager.
Amongst other responsibilities, I focus was on generating investment ideas using fundamental and technical analysis as well as detailed financial modeling. I holds a Bachelor of Commerce (Finance and Econometrics) and a candidate for the Level III examination of the Chartered Financial Analyst program and the Level II examination of the Chartered Alternative Investment Analyst program.